Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
845 results about "Inducer Cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Simultaneous stimulation and concentration of cells
InactiveUS6905874B2Maximizes stimulationBiocideImmunoglobulins against cell receptors/antigens/surface-determinantsT cellCells signal
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
Owner:LIFE TECH CORP
Methods for selectively stimulating proliferation of T cells
InactiveUS6905681B1Increase the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Owner:GENETICS INST INC +2
Simultaneous stimulation and concentration of cells
InactiveUS6867041B2Maximizes stimulationCulture processArtificial cell constructsDrug discoveryCells signal
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and / or stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
Owner:LIFE TECH CORP
Methods of treating HIV infected subjects
InactiveUS6905680B2Expanding population of cellIncrease the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:GENETICS INST INC +2
Optical depolarization of cardiac tissue
ActiveUS20090054954A1No painIncrease photosensitivitySurgical instrument detailsViruses/bacteriophagesManagement systemDepolarization
The invention provides a cardiac rhythm management system for stimulating a heart having photosensitive tissue, vectors useful to photosensitize cells expressing the vectors, and methods for light induced depolarization of cells.
Owner:CARDIAC PACEMAKERS INC
Toxin conjugated eph receptor antibodies
InactiveUS20090304721A1Prolong half-life in vivoIncrease local concentrationAnimal cellsImmunoglobulins against animals/humansCancer cellToxin Conjugates
Owner:SEATTLE GENETICS INC +1
Methods and Antibody Compositions for Tumor Treatment
ActiveUS20150266966A1Decreased killing of T-cellsReduce the burden onImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseCD20
The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
Owner:REGENERON PHARM INC
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
InactiveUS20080241139A1Enhanced T cell responseImprove responseAntibacterial agentsAntimycoticsDiseaseYeast
Adjuvant combinations comprising at least one microbial TLR agonist such as a whole virus, bacterium or yeast or portion thereof such a membrane, spheroplast, cytoplast, or ghost, a CD40 or 4-1BB agonist and optionally an antigen wherein all 3 moieties may be separate or comprise the same recombinant microorganism or virus are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers and HIV infection is also provided.
Owner:UNIV OF COLORADO THE REGENTS OF
Novel use of aim 3 acting as a tumor suppressor
InactiveUS20060046250A1Prevent proliferationPromote phosphorylationCompound screeningApoptosis detectionApoptosisInducer Cells
The present invention relates to novel uses of AIM3 acting as a tumor suppressor, and more particularly to methods for using an AIM3 protein or a nucleic acid encoding the protein to activate ATM or ATR and to treat ATM- or ATR-mediated diseases. The AIM3 protein according to the present invention interacts directly with ATM / ATR so as to activate ATM / ATR and proteins regulated by ATM / ATR. Also, the AIM3 protein upregulates tumor suppressor gene p53 and its target genes so as to not only inhibit the proliferation of cells but also to induce apoptosis.
Owner:SCHWARZ HERBERT +1
Small molecule inhibitors of MDM2 and the uses thereof
InactiveUS7759383B2Extended half-lifeIncrease the function(s) of p53BiocideOrganic chemistrySensitized cellMdm2 Protein
Owner:RGT UNIV OF MICHIGAN
Kinase Inhibitors And Uses Thereof
The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.
Owner:PURDUE RES FOUND INC
Method for improving induced pluripotent stem cell generation efficiency
ActiveUS20120276636A1Improve efficiencyImprove power generation efficiencyArtificial cell constructsArtificially induced pluripotent cellsHuman Induced Pluripotent Stem CellsCell generation
The present invention provides a method for improving iPS cell generation efficiency, which comprises a step of introducing a Myc variant having the following features: (1) having an activity to improve iPS cell generation efficiency which is comparative to, or greater than that of c-Myc; and (2) having a transformation activity which is lower than that of c-Myc; or a nucleic acid encoding the variant, in a nuclear reprogramming step. Also, the present invention provides a method for preparing iPS cells, which comprises a step of introducing the above Myc variant or a nucleic acid encoding the variant and a combination of nuclear reprogramming factors into somatic cells. Moreover, the present invention provides iPS cells comprising the nucleic acid encoding the Myc variant which can be obtained by the above method, and a method for preparing somatic cells which comprises inducing differentiation of the iPS cells.
Owner:KYOTO UNIV
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
InactiveUS20100111852A1Inhibit cell proliferationIn-vivo radioactive preparationsBiological material analysisProstate cancerCytotoxicity
Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
Owner:CHUGAI PHARMA CO LTD
Compositions that induce t cell help
The present invention relates, at least in part, to compositions, and related methods, comprising MHC II binding peptides. In one embodiment, the MHC II binding peptides comprise a peptide having at least 70% identity to a natural HLA-DP binding peptide, HLA-DQ binding peptide, or HLA-DR binding peptide.
Owner:SELECTA BIOSCI
Sc-beta cells and compositions and methods for generating the same
ActiveUS20150218522A1Ameliorate hyperglycemiaMetabolism disorderPancreatic cellsInducer CellsCell therapy
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
The invention provides compositions and methods for promoting apoptosis of cancer cells, and methods for treating cancer. The compositions comprise cyclin dependent kinase inhibitor and an agent that induces cellular differentiation. The methods of promoting apoptosis of cancer cells involve the co-administration to the cancer cells of a cyclin dependent kinase inhibitor and an agent that induces cell differentiation. The method for treating cancer involves the co-administration of a cyclin dependent kinase inhibitor and an agent that induces cellular differentiation to a patient. Examples of cyclin dependent kinase inhibitors include histone deacetylase inhibitors, protein kinase C activators, retinoids, and Vitamin D3.
Owner:VIRGINIA COMMONWEALTH UNIV
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
InactiveUS20050136125A1Effective in inducing stasisReduces and eliminates amount of oxygenBiocideIn-vivo radioactive preparationsInducer CellsIn vivo
The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and / or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.
Owner:FRED HUTCHINSON CANCER RES CENT
Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
InactiveUS20100092457A1High expressionAntibody mimetics/scaffoldsMicrobiological testing/measurementAntigen bindingBULK ACTIVE INGREDIENT
Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
Owner:CHUGAI PHARMA CO LTD +1
Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
Owner:NEOCUTIS
Sc-beta cells and compositions and methods for generating the same
InactiveUS20170029778A1Ameliorate hyperglycemiaMetabolism disorderPancreatic cellsInducer CellsCell therapy
Owner:JANSSEN BIOTECH INC +1
Conformationally Constrained Smac Mimetics And The Uses Thereof
InactiveUS20080132485A1Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Methods for the induction of a cell to enter the islet 1+ lineage and a method for the expansion thereof
InactiveUS20110033430A1Enhancing the wnt/β-catenin pathwayIncreasing and enhancing wnt signalingBiocideGenetic material ingredientsProgenitorISL1
The present invention relates to methods for the induction and a cell to enter the Islet 1+ (Isl1+) lineage and methods for expansion of cells of islet 1+ lineage. One aspect of the present invention relates to methods to induce a cell to enter the islet 1+ lineage, and more particularly to a method to induce a cell to enter a the Isl1+ lineage to become an Isl1+ progenitor that is capable of differentiating along multiple different lineages such as a endothelial lineage, a smooth muscle lineage or a cardiac lineage. In particular, one embodiment present invention relates to methods to induce a cell to enter the Isl1+ lineage by inhibiting a wnt signalling pathway in the cell. Another aspect of the present invention relates to methods to expand a cell of the Isl1+ lineage, such as a Isl1+ progenitor by activating a wnt signalling pathway in the Isl1+ progenitor. Another aspect of the present invention relates to use of cells of the isl1+ lineage in subjects for therapeutic and preventative treatment of cardiovascular diseases.
Owner:THE GENERAL HOSPITAL CORP
Use of polymeric nanoparticles for vaccine delivery
InactiveUS20080044484A1Enhance antigen presentationImprove efficiencyBiocidePowder deliveryCancer cellT lymphocyte
The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.
Owner:RGT UNIV OF CALIFORNIA
Cell regulatory genes, encoded products, and uses related thereto
InactiveUS6946256B1Peptide/protein ingredientsImmunoglobulins against animals/humansSuppressorApoptosis
This application describes the cloning of p63, a gene at chromosome 3q27-29, that bears homology to the tumor suppressor p53. The p63 gene encodes at least six different isotypes. p63 was detected in a variety of human and mouse tissue and demonstrates remarkably divergent activities, such as the ability to transactivate p53 reporter genes and induce apoptosis. Isotopes of p63 lacking a transactivation domain act as dominant negatives towards the transactivation by p53 and p63.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +2
Method for polyclonal stimulation of t cells by flexible nanomatrices
ActiveUS20140087462A1Improves in-vitro stimulation of T-cellsSaving viability of cellMammal material medical ingredientsCell culture supports/coatingBiological activationPolymer
The present invention provides a method polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a flexible matrix, wherein said matrix is of polymeric material; and b) attached to said polymeric flexible matrix one or more polyclonal stimulatory agents which provide activation signals to the T cells; thereby activating and inducing the T cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices. If the stimulatory agents are attached to separate beads, fine-tuning of nanomatrices for the stimulation of the T cells is possible.
Owner:MILTENYI BIOTEC B V & CO KG
Differentiation of human embryonic stem cells to cardiomyocytes
InactiveUS20070161107A1Improve compatibilityPromote differentiationArtificial cell constructsSkeletal/connective tissue cellsCardiac muscleCo culturing
A method for inducing cardiomyocyte differentiation of a hES cell, the method comprising co-culturing the hES cell with a cell excreting at least one cardiomyocyte differentiation inducing factor or with an extracellular medium therefrom, under conditions that induce differentiation, cells and cell populations so produced, and uses of the cells.
Owner:MUMMERY CHRISTINE LINDSAY +2
Compositions and methods for induction of th17 cells
ActiveUS20170028061A1Induced proliferationInduce accumulationBacteria material medical ingredientsSaccharide peptide ingredientsBacteroidesIntestinal structure
Owner:THE UNIV OF TOKYO +2
Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
Owner:A & G PHARMA
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
Owner:SEAGEN INC
Toxin conjugated eph receptor antibodies
InactiveUS20110280892A1Prolong half-life in vivoIncrease local concentrationAnimal cellsBacteriaCancer cellAntiendomysial antibodies
Owner:MEDIMMUNE LLC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com